Anti-Addiction Agent

I read with interest your story "Government To Industry: Join War On Drugs" [The Scientist, Nov. 26, 1990, page 1]. For the last three years, our company, NDA International Inc., has focused upon the development of an anti-addiction agent, Ibogaine, as an interrupter of heroin and cocaine dependency. NDA International has funded research projects in the United States, Canada, and the Netherlands. These have all supported our claims for ENDABUSE (Ibogaine HCl). Research performed at Erasmus Uni

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

NDA International has funded research projects in the United States, Canada, and the Netherlands. These have all supported our claims for ENDABUSE (Ibogaine HCl). Research performed at Erasmus University, Rotterdam, provided data that ENDABUSE reduced certain behavioral characteristics in naloxone-precipitated morphine withdrawal. Investigators at Albany Medical College have shown reversal and blockade of morphine-induced dopamine increases in the nucleus accumbens and striatum as well as decreases in self-administration of morphine by Ibogaine-treated rats.

Preclinical studies at the Medical College of Virginia, Richmond, and the University of Michigan Medical School, Ann Arbor, demonstrated that Ibogaine was neither an opiate nor an antagonist, does not cause physical dependency itself, and attenuates morphine withdrawal in rats and primates. Anecdotal field studies and experimental therapeutic applications, conducted outside the U.S., have demonstrated that Ibogaine will eliminate narcotic withdrawal for both heroin and methadone while removing the craving to continue using opiate narcotics or cocaine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Howard Lotsof

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio